BiotechTube
Home/Pipeline/Biosimilar Pembrolizumab

Biosimilar Pembrolizumab

Oncology

Phase 3ActiveN/A

Key Facts

Indication
Oncology
Phase
Phase 3
Status
Active
Company
Organon (2)

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

View full company profile

Therapeutic Areas

Women's HealthBiosimilarsCardiovascularRespiratoryDermatologyNeurologyAutoimmune

Other Oncology Drugs

DrugCompanyPhase
mRNA Anticancer VaccineSunshine BiopharmaPreclinical Research
Biosimilar BevacizumabOrganon (2)Phase 3
BCL-2 Inhibitor ProgramVincerx PharmaPreclinical
KEAP1 Activator ProgramVividion TherapeuticsPhase 1
Personalized Medicine Assays (Patient-Derived Explants)Aurita BioscienceResearch-Use Only
CDK2-CyclinE1 & CDK2-CyclinA2 AssayAurora BiolabsCommercial
POLQ & eIF4E AssayAurora BiolabsCommercial
PKMYT1 & WEE1 AssayAurora BiolabsCommercial
NTP42ATXA TherapeuticsPreclinical
Athebody® DARPins for pHLA-binding T-Cell EngagersAthebioPre-clinical
Dual-Targeting CAR-T ProgramsFactor BiosciencePre-clinical
Molecular Diagnostic ServicesGenloxaCommercial